Short Interest in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Rises By 23.3%

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 6,208,105 shares, an increase of 23.3% from the January 15th total of 5,033,852 shares. Approximately 6.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is currently 5.0 days. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is currently 5.0 days. Approximately 6.7% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPS. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways in the 4th quarter worth about $38,000. Advisory Services Network LLC acquired a new position in Compass Pathways in the third quarter valued at about $41,000. China Universal Asset Management Co. Ltd. grew its stake in Compass Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after buying an additional 5,817 shares during the last quarter. BIT Capital GmbH acquired a new stake in shares of Compass Pathways during the third quarter worth approximately $54,000. Finally, Conservest Capital Advisors Inc. raised its stake in shares of Compass Pathways by 32.5% in the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock valued at $57,000 after acquiring an additional 5,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Up 10.7%

NASDAQ CMPS opened at $8.45 on Thursday. Compass Pathways has a 1-year low of $2.25 and a 1-year high of $8.90. The company has a market capitalization of $811.37 million, a price-to-earnings ratio of -3.11 and a beta of 1.92. The stock’s 50 day moving average is $6.80 and its two-hundred day moving average is $5.91. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.55.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CMPS. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Royal Bank Of Canada increased their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday. Canaccord Genuity Group boosted their price objective on shares of Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Finally, Compass Point set a $15.00 price target on Compass Pathways in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average target price of $17.56.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Positive Phase III topline: COMP360 met its primary endpoint in a late‑stage trial (statistically significant symptom reduction, rapid onset and durability through later weeks), strengthening the drug’s clinical and regulatory outlook and lifting sector sentiment. Read More.
• Positive Sentiment: Analyst support: Analysts have an average rating of “Moderate Buy,” which can sustain inflows and provide selling-pressure resistance after the clinical win. Read More.
• Neutral Sentiment: Options and trading flows: Unusually large call option volume suggests short-term speculative/bullish positioning; this can amplify intraday moves but doesn’t change fundamentals.
• Neutral Sentiment: Confusing short‑interest report: recent data showing zero shares and NaN changes appears unreliable and offers no clear signal to investors; ignore until clarified by a trustworthy data release.
• Negative Sentiment: Equity raise and dilution risk: Compass launched a proposed $150M public offering to fund development and commercialization. The raise — and reporting that the offering price is deeply discounted to recent levels — prompted pre‑market weakness and creates near‑term dilution that can cap upside until proceeds are deployed. Read More.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.